The Middle East and Africa CDMO Market was valued at approximately USD 6.12 Billion in 2025 and is projected to grow at a CAGR of 6.90% during the forecast period of 2026 to 2035, reaching around USD 11.96 Billion by 2035. The market growth is being driven by increasing pharmaceutical outsourcing, rising demand for biologics, and expanding healthcare infrastructure across the Middle East and Africa region.

What Is a CDMO?

A Contract Development and Manufacturing Organisation (CDMO) provides end-to-end services for pharmaceutical and biotechnology companies, including drug development, manufacturing, and packaging. CDMOs enable companies to outsource complex processes, reduce costs, and accelerate time-to-market for new drugs and therapies.

Why Is the MEA CDMO Market Growing?

The MEA CDMO market is expanding due to the increasing demand for cost-efficient drug development and manufacturing solutions. Pharmaceutical companies are outsourcing production to specialised CDMOs to focus on core competencies such as research and marketing. Additionally, the rising prevalence of chronic diseases, increasing investment in biotechnology, and growing demand for biosimilars and biologics are fueling market growth.

Request a Free Sample Report: https://www.expertmarketresearch.com/reports/mea-cdmo-market/requestsample

Recent Industry Developments and Updates

The CDMO industry in the Middle East and Africa is witnessing several key developments:

  • Increasing investments in pharmaceutical manufacturing facilities
  • Growing focus on biologics and biosimilar production
  • Strategic partnerships between global pharma companies and regional CDMOs
  • Expansion of contract manufacturing capabilities
  • Adoption of advanced technologies in drug development

These developments highlight the region’s transition toward becoming a key hub for pharmaceutical outsourcing.

Key Drivers Fueling Market Growth

  • Rising Pharmaceutical Outsourcing
  • Growing Demand for Biologics and Biosimilars
  • Expanding Healthcare Infrastructure
  • Increasing Investment in Biotechnology
  • Cost Efficiency and Operational Flexibility
  • Rising Prevalence of Chronic Diseases

Are CDMOs Important in the Pharmaceutical Industry?

Yes, CDMOs play a critical role in the pharmaceutical industry by enabling efficient drug development and manufacturing. They help companies reduce capital investment, improve scalability, and ensure compliance with regulatory standards, making them essential partners in modern drug production.

Emerging Trends Shaping the Market

  • Increasing focus on biologics and advanced therapies
  • Growth of biosimilars manufacturing
  • Expansion of local pharmaceutical production capacities
  • Rising adoption of advanced manufacturing technologies
  • Strengthening regulatory frameworks across the region
  • Increasing collaborations and partnerships

Middle East and Africa CDMO Market Segmentation

Breakup by Service

  • Contract Development
  • Contract Manufacturing

Contract manufacturing dominates the market due to high demand for large-scale drug production.

Breakup by Product

  • Small Molecules
  • Biologics

Biologics are witnessing significant growth due to rising demand for advanced therapies.

Breakup by End User

  • Pharmaceutical Companies
  • Biotechnology Companies
  • Others

Pharmaceutical companies hold a major share due to extensive outsourcing needs.

Breakup by Region

  • Saudi Arabia
  • United Arab Emirates
  • Nigeria
  • South Africa
  • Others

Which Region Leads the Market?

Countries such as Saudi Arabia and the United Arab Emirates are leading the MEA CDMO market due to strong healthcare investments, government initiatives, and expanding pharmaceutical manufacturing infrastructure.

Frequently Asked Questions (FAQs)

Q1. What was the MEA CDMO market size in 2025?
The market reached USD 6.12 Billion in 2025.

Q2. What is the projected CAGR of the market?
The market is expected to grow at a CAGR of 6.90% during 2026–2035.

Q3. What will be the market value by 2035?
The market is projected to reach USD 11.96 Billion by 2035.

Q4. What are the key drivers of the market?
Key drivers include pharmaceutical outsourcing, biologics demand, and healthcare infrastructure growth.